Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.49 |
| ▸ | NOS2 | P35228 | 8/20 | 0.49 |
| ▸ | NOS3 | P29474 | 6/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014825 | 0.89 | SLC11A2 (0.46) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL13560707 | 0.81 | HRH3 (0.50) | NOS1NOS2NOS3LOXL2SMN1; SMN2 | |
| SCHEMBL36008 | 0.81 | LOXL2 (0.71) | NOS1NOS2NOS3PNMTENPP2 | |
| SCHEMBL10422276 | 0.81 | LOXL2 (0.71) | NOS1NOS2NOS3PNMTENPP2 | |
| SCHEMBL13560719 | 0.80 | TP53 (0.44) | ALDH1A1SMN1; SMN2SLC11A2KIF11TAAR1 | |
| SCHEMBL30515543 | 0.78 | MAOB (0.52) | ALDH1A1CYP3A4SLC11A2TAAR1 | |
| SCHEMBL22342264 | 0.78 | SLC11A2 (0.39) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL28762449 | 0.78 | ENPP2 (0.45) | NOS1NOS2NOS3ENPP2SLC11A2 | |
| SCHEMBL14099205 | 0.78 | FOLH1 (0.42) | NOS1NOS2NOS3ALDH1A1SMN1; SMN2 | |
| SCHEMBL16176633 | 0.78 | MAOB (0.52) | ALDH1A1CYP3A4SLC11A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2019150138-A1 | CONJUGATES OF CYCLODEXTRINS AND DEFERASIROX OR ANALOGUES THEREOF | THE UNIVERSITY OF SUSSEX (GB) | 2019-08-08 | — | — | WO | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20120277184-A1 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES | Innovative biologics, Inc (US) | 2012-11-01 | — | — | US | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080234182-A1 | Compound having a symmetry and size capable of fitting to an opening of the pore of a pore-forming pathogen for binding such that upon binding, the pore or prepore is blocked, especially cyclodextrin derivatives; combatting biological warfare; drug screening; drug design | INNOVATIVE BIOLOGICS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234182-A1 | Compound having a symmetry and size capable of fitting to an opening of the pore of a pore-forming pathogen for binding such that upon binding, the pore or prepore is blocked, especially cyclodextrin derivatives; combatting biological warfare; drug screening; drug design | INNOVATIVE BIOLOGICS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| CN-1976907-A | Heterocyclic amide compound and use thereof as an MMP-13 inhibitor | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | NOS1 1011/4885NOS2 1125/4885NOS3 726/4885 |
| US-20080234182-A1 | Compound having a symmetry and size capable of fitting to an opening of the pore of a pore-forming pathogen for binding such that upon binding, the pore or prepore is blocked, especially cyclodextrin derivatives; combatting biological warfare; drug screening; drug design | HAVCR2, GZMB, PRF1 | NOS1 4521/4885NOS2 4710/4885NOS3 4680/4885 |
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | NOS1 2429/4885NOS2 1865/4885NOS3 2515/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | NOS1 719/4885NOS2 606/4885NOS3 424/4885 |
| US-20120277184-A1 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES | ANTXR2, LTA, GZMB | NOS1 2939/4885NOS2 2971/4885NOS3 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.